SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

BigBear.ai Holdings, Inc. engages in data-driven decision dominance and advanced analytics that provide its customers with a competitive advantage in a world driven by data that is growing in terms of volume, variety, and velocity. The firm operationalizes artificial intelligence and machine learning at scale through its end-to-end data analytics platform. It deploys its observe, orient and dominate products to customers throughout the defense, intelligence, and commercial markets. The company was founded in 2020 and is headquartered in McLean, VA.

BigBear.ai Holdings Inc

BigBear.ai is currently a hot topic as investors eagerly await a crucial shareholder vote on increasing authorized shares, with high speculation that significant government AI contract announcements are being held until after its passage. This has sharply divided the community, with many anticipating a major short squeeze and institutional accumulation in the defense AI sector, while skeptics warn of potential dilution and perceived overvaluation.

Oracle Corp. engages in the provision of products and services that address aspects of corporate information technology environments, including applications and infrastructure technologies. It operates through the following business segments: Cloud and License, Hardware, and Services. The Cloud and License segment markets, sells, and delivers enterprise applications and infrastructure technologies through cloud and on-premise deployment models including cloud services and license support offerings. The Hardware segment provides infrastructure technologies including Oracle Engineered Systems, servers, storage, industry-specific hardware, operating systems, virtualization, management, and other hardware-related software. The Services segment offers consulting, advanced support, and education services. The company was founded by Lawrence Joseph Ellison, Robert Nimrod Miner, and Edward A. Oates on June 16, 1977 and is headquartered in Austin, TX.

Oracle Corp.

Oracle is trending amidst intense debate, primarily driven by community anticipation for a potential TikTok deal closing soon, which some believe will catalyze a significant rebound. However, the stock is simultaneously facing strong bearish pressure and discussion following news of a bondholder lawsuit alleging undisclosed debt incurred for its substantial AI infrastructure buildout, raising concerns about its financial stability within the broader tech sector.

Microsoft Corp. engages in the development and support of software, services, devices, and solutions. It operates through the following segments: Productivity and Business Processes, Intelligent Cloud, and More Personal Computing. The Productivity and Business Processes segment is composed of products and services relating to productivity, communication, and information services such as Office Commercial, Office Consumer, LinkedIn, and Dynamics business solutions. The Intelligent Cloud segment consists of public, private, and hybrid server products and cloud services for businesses and developers, as well as enterprise and partner services. The More Personal Computing segment refers to products and services including Windows operating system, Windows cloud services, Surface, HoloLens, personal computer accessories, Xbox hardware, Xbox Cloud Gaming, Microsoft News, and Microsoft Edge. The company was founded by Paul Gardner Allen and William Henry Gates, III in 1975 and is headquartered in Redmond, WA.

Microsoft Corporation

Microsoft Corp

Microsoft is a major talking point due to ongoing legal challenges from Elon Musk concerning its partnership with OpenAI, which coincides with broad community frustration over its recent underperformance. Despite some labeling it "garbage," many investors are eyeing the current pullback as a strategic buying opportunity, betting on its strong fundamentals and anticipating clarity around its significant AI investments ahead of upcoming earnings.

Netflix, Inc. engages in providing entertainment services. It also offers activities for leisure time, entertainment video, video gaming, and other sources of entertainment. It operates through the United States and International geographic segments. The company was founded by Marc Randolph and Wilmot Reed Hastings on August 29, 1997 and is headquartered in Los Gatos, CA.

Netflix Inc.

Netflix Inc

Netflix is trending as its stock experiences a significant sell-off following a soft Q1 guidance and market anxieties over its all-cash Warner Bros. Discovery acquisition. While some in the community highlight increased debt and competitive risks from the deal, many are viewing the substantial price drop as an oversold opportunity for a market leader with strong fundamentals, anticipating a rebound.

Hims & Hers Health, Inc. operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.

Hims & Hers Health Inc - Ordinary Shares - Class A

Hims & Hers Health Inc

Hims & Hers Health Inc. is trending amidst a considerable multi-month price decline, baffling many who note a lack of specific negative news and sparking community speculation around market manipulation. Bears point to increasing competition from giants like Amazon and evolving GLP-1 market dynamics, while bulls highlight HIMS's expanding platform in personalized digital healthcare, vertical integration, and strong growth as reasons for an impending rebound and potential short squeeze.

SSgA Active Trust - SPDR S&P 500 ETF Trust

The SPDR S&P 500 ETF Trust is experiencing a significant surge, primarily driven by market interpretations of recent geopolitical discussions, notably clarifications around Greenland that have eased immediate fears. This aggressive rally is widely seen by the community as a powerful short squeeze, catching bears off guard and leading to extensive discussion around options mechanics and a "V-shaped" market reversal. While many celebrate the rebound, skepticism persists among some, who view the move as a temporary pump or manipulation amidst lingering concerns over potential EU trade tensions and upcoming housing policy announcements.

Bitcoin is the world's first decentralized cryptocurrency, created in 2009 by the pseudonymous Satoshi Nakamoto. It enables peer-to-peer electronic cash transactions without intermediaries like banks or governments, operating on a blockchain secured by Proof of Work mining and the SHA-256 cryptographic algorithm.   With a fixed supply cap of 21 million coins and programmatic halvings every four years that reduce miner rewards, Bitcoin is designed as a deflationary digital asset often called "digital gold." Its value stems from solving the double-spending problem without trusted intermediaries, creating the first truly scarce digital asset with censorship resistance and permissionless access that no government, corporation, or individual can control.  Bitcoin operates as a decentralized peer-to-peer network where transactions are recorded on a public ledger called the blockchain, distributed across thousands of computers globally. Transactions are grouped into blocks added approximately every 10 minutes through mining, where specialized computers compete to solve complex mathematical puzzles.   Bitcoin has achieved mainstream adoption through multiple vectors. The January 2024 SEC approval of 11 spot Bitcoin ETFs opened Bitcoin investment to traditional finance participants, and corporations like Strategy (formerly MicroStrategy) are using Bitcoin as a treasury reserve asset to protect against currency debasement, offering MSTR holders amplified exposure to Bitcoin.   The Bitcoin ecosystem continues to evolve with innovations like Ordinals, which emerged in January 2023 to enable NFT-like functionality directly on Bitcoin, and BRC-20 tokens, an experimental standard for creating fungible tokens using Ordinal inscriptions. BTCFi (Bitcoin Finance) represents emerging financial applications extending beyond Bitcoin's traditional role, with protocols like Babylon allowing Bitcoin holders to stake BTC to secure Proof of Stake chains.

Bitcoin

Bitcoin is seeing intense discussion driven by former President Trump's remarks from Davos, emphasizing his supportive stance towards the crypto industry and potential legislative action. This has polarized the community, with many anticipating a major rally and a "super cycle" in digital assets, while a segment expresses caution, labeling recent price action as a "bear trap" amid ongoing market volatility.

Invesco Capital Management LLC - Invesco QQQ Trust Series 1

The Invesco QQQ Trust Series 1 is trending due to extreme intraday volatility, as an initial rally following President Trump's softened rhetoric on Greenland at Davos was abruptly reversed. This sharp reversal, coupled with news of the EU suspending trade deals amid tariff tensions, has fueled widespread community discussion about a market 'pump and dump' event. Traders are actively navigating these rapid swings, with many positioning for further potential declines.

PAVmed, Inc. is a multi-product life sciences company, which engages in the innovation, development, acquisition, and commercialization of products that target unmet medical needs with large addressable market opportunities. Its products include Lucid Diagnostics and Veris Health. The company was founded by Lishan Aklog and Brian J. deGuzman on June 26, 2014 and is headquartered in New York, NY.

PAVmed Inc

PAVmed Inc. is trending as its subsidiary, Lucid Diagnostics, secured a significant contract with the U.S. Department of Veterans Affairs for its EsoGuard Esophageal DNA Test, expanding access across a large healthcare system. This news, coupled with the stock's low float characteristics, has ignited intense community discussion and propelled highly volatile trading activity.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is experiencing significant trading volatility, sparking intense debate among investors after a rapid price fluctuation despite recent analyst upgrades to a $137 price target. The "Spacemob" community remains fiercely bullish, anticipating upcoming satellite launches and commercial agreements, while others are actively trading the dramatic swings and discussing potential entry points.

statis crypto Watchlist

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Earnings Outlook For Cellectar Biosciences

Cellectar Biosciences (CLRB) stock tumbled over 17% on Tuesday after the company announced an agreement with several institutional investors to exercise certain existing warrants for gross proceeds of approximately $5.8 million.Cellectar <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cellectar.com/news-media/press-releases/detail/377/cellectar-biosciences-inc-enters-into-agreements-to-raise">stated</a> that a total of 1.05 million existing warrants were exercised. The company now intends to use the net proceeds for working capital and general corporate purposes in addition to funding the early-stage trial of its CLR 125 compound in triple-negative breast cancer.The capital raise comes on the heels of Cellectar <a class="st-link-external" target="_blank" rel="noopener noreferrer nofollow" href="https://www.cellectar.com/news-media/press-releases/detail/376/cellectar-biosciences-announces-european-medicines-agency">announcing</a> that it intends to submit a conditional marketing authorization application to the European Medicines Agency for Iopofosine I 131 as a treatment for refractory Waldenstrom macroglobulinemia in early 2026, following advice from the agency’s Scientific Advice Working Party (SAWP).The company stated that it anticipates European Approval by 2027 and commercial availability of the therapy in the 30 countries represented by the EMA in the same year.“We believe this regulatory success is substantial as it further supports Cellectar’s plans to pursue worldwide approval, including a New Drug Application (NDA) with the U.S. Food and Drug Administration (FDA) under an accelerated approval pathway,” CEO James Caruso said on Monday, while noting that an NDA submission is contingent upon the company obtaining additional funding to initiate a confirmatory trial.Oppenheimer, which has a ‘Perform rating’ on <a href="https://stocktwits.com/symbol/CLRB">CLRB shares</a>, subsequently noted that the news is a substantial positive catalyst that should bolster the company’s efforts to partner the Iopofosine I 131 program.On Stocktwits, retail sentiment around CLRB jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours, while message volume rose from ‘high’ to ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:1372/132;" src="https://news.stocktwits-cdn.com/Screenshot_2025_10_07_at_11_30_27_AM_png_09a789f2e6.webp" alt="CLRB's Sentiment Meter and Message Volume as of 11:30 a.m. ET on Oct. 07, 2025 | Source: Stocktwits" width="1372" height="132"><figcaption>CLRB's Sentiment Meter and Message Volume as of 11:30 a.m. ET on Oct. 07, 2025 | Source: Stocktwits</figcaption></figure>A Stocktwits user dismissed the decline in the stock price.<stembedurl>https://stocktwits.com/EvenBetter99/message/631308393</stembedurl>Another user expressed hopes about an impending rally in the shares.<stembedurl>https://stocktwits.com/Slab6/message/631300689</stembedurl>CLRB stock is down 43% this year and approximately 92% over the past 12 months.&nbsp;Read also:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/ford-shares-slump-after-reports-of-fire-at-aluminum-supplier-plant/ch6PW0NR3ha">Ford Shares Slump 5% After Reports Of Fire At Aluminum Supplier Plant: Retail Dismisses The Dip As ‘Short-Lived’</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Stock market down on a black background. | Image source: Yuichiro Chino via Getty Images

Cellectar Biosciences Stock Drops 17% On $5.8M Fundraise: Retail Awaits An ‘Impending’ Rally

The company announced that it now intends to utilize the net proceeds for working capital and general corporate purposes, in addition to funding the early-stage trial of its CLR 125 compound in triple-negative breast cancer. 

Equity

The company announced that it now intends to utilize the net proceeds for working capital and general corporate purposes, in addition to funding the early-stage trial of its CLR 125 compound in triple-negative breast cancer. 


All You Need to Know About Cellectar Biosciences (CLRB) Rating Upgrade to Buy

Cellectar Biosciences (CLRB) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

Are Medical Stocks Lagging  Anixa Biosciences (ANIX) This Year?

Zacks Industry Outlook Highlights Insulet, MacroGenics, Cellectar Biosciences and Allurion Technologies

4 Medical Product Stocks to Watch From a Challenging Industry

Cellectar Biosciences, Inc. engages in the development of phospholipid drug conjugates (PDCs) for the treatment and imaging of cancer. Its portfolio includes CLR 131, which seeks to treat relapse or refractory multiple myeloma, CLR 125, which intends to treat micro metastatic disease, CLR 124, which could detect tumors and metastases in a broad range of cancers, and CLR 1502, a cancer-targeting near-infrared-fluorophore optical imaging PDC for intraoperative tumor and tumor margin illumination. The company was founded on June 24, 1996 and is headquartered in Florham Park, NJ.

Cellectar Biosciences Inc

Up 10% or more

0% to up 9%

Down 1% to 9%

Down 10% or more

The S&P 500 enters 2026 after a strong run. What kind of return do you expect this year?

How will the S&amp;P 500 perform in 2026?

CLRB
Cellectar Biosciences Inc

Feed

News

Sentiment

Earnings

Fundamentals

Info

Poll

Latest CLRB News

CLRBCellectar Biosciences Inc